AION Labs, an Israel-based AI-powered drug discovery partnership between global pharmaceutical and technology companies, launches ProPhet, a startup that uses artificial intelligence to find small molecules for drug discovery .
ProPhet was founded in response to an AION Labs startup challenge focused on AI-powered novel high-affinity small molecule drug discovery.
The aim is to speed up the early stages of drug discovery by focusing on proteins that are difficult due to limited information and significantly reducing the time and cost of identifying potential drug candidates against these targets. It’s about meeting the market’s needs to upgrade, refine and enhance.
According to the company, ProPhet uses cutting-edge machine learning technologies such as diffusion models and LLM to address biological and computational obstacles by creating new and optimized algorithms.
“Proteins can assume a variety of possible conformational states under the influence of their surroundings,” Prophet CEO Tom Shani said in a statement.
“Our platform allows us to assess these various conditions and screen vast small molecule libraries against them in a highly scalable way. It has provided us with the opportunity to partner with players and provided the perfect environment for our growth, ensuring that we are aligned with industry priorities and needs.”
Mati Gill, CEO of AION Labs, said ProPhet’s approach is particularly important because the majority of the drugs developed are made up of small molecules and ProPhet’s approach is widely applicable to a wide range of treatments.
“Dr. Shani has assembled an ideal team for this field, with the perfect combination of biology, chemistry, and computational expertise. We are excited to support ProPhet with the resources and connections needed for success. ,” Gill said in a statement.
bigger trends
Founded in 2021, AION labs works with major pharmaceutical companies such as AstraZeneca, Merck, Pfizer, Israel Biotechnology Fund, and Teva Pharmaceuticals, as well as technology company Amazon Web Services and German independent research institute BioMedX I’m doing it.
In March, AION Labs launched CombineAble.AI, a startup aimed at accelerating the development of therapeutics by addressing challenges associated with antibody design. The company develops a platform that combines computational methods and AI for biomolecular simulations aimed at developing new biotherapeutics.
In January, AION Labs launched a new startup, TenAces. The company uses AI that integrates biology and machine learning algorithms to discover molecular adhesion therapies that improve the degradation of targeted proteins.
In 2023, AION launched its second startup, DenovAI. DenovAI is an AI-enabled computational biophysics platform that can discover potential antibodies against specific epitopes (the parts of antigen molecules recognized by the immune system that antibodies bind to). The platform designs antibodies from scratch and suggests which candidates are most likely to produce effective drugs.
The company launched OMEC.AI in 2022. It builds an AI-enabled computational platform that allows researchers to assess the clinical trial readiness of drug candidates, identify hidden safety liabilities, and suggest experiments to fill identified gaps. It is intended to.
PromiseBio is another AION Labs company that provides epiproteomic analysis for precision medicine, with the goal of deciphering biological insights into complex chronic diseases, including autoimmune diseases.
